Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMISO PET and MRI for Tumor Hypoxia in Newly Diagnosed Glioblastoma
NCT00902577Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2009
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluoromisonidazole in glioblastoma multiforme (GBM), sponsored by National Cancer Institute. Primary endpoint: Overall Survival at 5 years. Started Aug 2009; status: completed.
02
Drugs
fluoromisonidazole
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00902577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00902577.